JKJoshua P. Klopper

Joshua P. Klopper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua P. Klopper has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Vibha Sharma

    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, 12801 E. 17th Ave., Aurora, CO 80045, USA

    2 shared publications
  • Andrew Berenz

    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, USA

    1 shared publication
  • Anna Kerege

    University of Colorado School of Medicine

    1 shared publication
  • Antonio Jimeno

    The University of Colorado School of Medicine

    1 shared publication
  • Bryan Haugen

    The University of Colorado School of Medicine

    1 shared publication
  • Bryan R. Haugen

    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA

    1 shared publication

Latest Publications

  • A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer

    by Joshua Klopper, Madeleine Kane, Antonio Jimeno, Sharon Sams, Jena French, Laura Pike, Kenneth Tompkins, Bryan Haugen


  • Open Access

    Consumptive Hypothyroidism Resulting from Hepatic Vascular Tumors in an Athyreotic Adult

    by David Howard, Francisco G. La Rosa, Stephen Huang, Domenico Salvatore, Michelle Mulcahey, Jennifer Sang-Lee, Michael Wachs, Joshua P. Klopper

    Context: Consumptive hypothyroidism is a rare syndrome resulting from increased catabolism of T4 and T3 by increased type 3 iodothyronine deiodinase (D3) activity. Consumptive hypothyroidism has primarily been described as a paraneoplastic syndrome in infants as well as in two adults with D3-expressing tumors. Objective: The aim of the study was to report the third case of consumptive hypothyroidism in an adult and the first in an athyreotic patient. Design, Setting, and Patient: We present a 38-yr-old athyreotic female who was euthyroid on a stable therapeutic dose of thyroid hormone for many years and then developed marked hyperthyrotropinemia, coincident with the discovery of large D3-expressing hepatic vascular tumors. The patient also had low serum T3 and elevated serum rT3. Hyperthyrotropinemia transiently worsened after surgical resection of the vascular tumors and then persisted for 3 wk after the operation, despite further increases in levothyroxine therapy. Intervention: The patient's vascular tumor and adjacent normal liver parenchyma were probed with a polyclonal antibody directed against D3. Main Outcome Measures and Results: D3 immunostaining of the patient's vascular tumor was positive, with no significant immunoreactivity in the adjacent normal hepatic tissue. Conclusions: This is the third case report of consumptive hypothyroidism in an adult and the first in an athyreotic individual. This case demonstrates that hyperthyrotropinemia may persist after partial liver resection, possibly from the hepatic resection itself.


  • Thyroid Cancer Resistance to Vitamin D Receptor Activation Is Associated with 24-Hydroxylase Levels But Not the ff FokI Polymorphism

    by Vibha Sharma, Deborah Fretwell, Zachary Crees, Anna Kerege, Joshua P. Klopper

    Background: The vitamin D receptor (VDR) has been studied as a novel target for cancer therapy in many tissue types as VDR ligands decrease cell proliferation in vitro and decrease tumor growth in vivo in sensitive cells. The objective of this study was to analyze the response to VDR agonist therapy in a panel of validated thyroid cancer cells and assess genetic markers predicting sensitivity and resistance to calcitriol and the noncalcemic analog DP006. Methods: Thyroid cancer cell lines were analyzed for VDR and RXR protein by Western blot. Cell growth after VDR agonist treatment (calcitriol or DP006) was assessed after 6 days of treatment by viable cell assay. To investigate calcitriol/DP006 resistance in VDR-expressing cells, the VDR was sequenced and 1-α and 24-hydroxylase mRNA expression was assessed. Results: VDR protein was variably expressed in the thyroid cancer cell lines and its presence was not sufficient for decreased viable cell count in response to calcitriol or DP006. The most sensitive cells (TPC1) have an ff FokI VDR polymorphism and the most resistant cells (HTh7 and 8505C) have an FF FokI VDR. This is a unique finding given that the balance of the literature of VDR polymorphisms describes an association of the ff FokI polymorphism with cancer risk and/or decreased VDR transactivation. 1-α and 24-hydroxylase mRNA expression before and after VDR agonist therapy was examined. 1-α-Hydroxylase levels did not change after calcitriol treatment. However, we found that higher baseline 24-hydroxylase levels and/or lower stimulation of 24-hydroxylase levels after calcitriol treatment were associated with relative resistance to calcitriol/DP006. Conclusions: The VDR represents a novel therapeutic target in poorly differentiated thyroid cancer; however, the efficacy of VDR agonist therapy to decrease viable thyroid cancer cell count cannot be predicted solely on the presence of the VDR. The FF FokI VDR genotype and high baseline 24-hydroxylase levels were associated with relative resistance to calcitriol and DP006. Therefore, identifiable markers of sensitivity or resistance to VDR agonist therapy may allow for a personalized use of these agents in poorly differentiated thyroid cancer.


  • Open Access

    Combination PPARγand RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2

    by Joshua P. Klopper, Vibha Sharma, Reid Bissonnette, Bryan R. Haugen

    Nuclear hormone receptors, including RXR and PPARγ, represent novel therapeutic targets in melanoma. We have previously shown that the DRO subline of the amelanotic melanoma A375 responds to rexinoid and thiazolidinedione (TZD) treatmentin vitroandin vivo. We performed microarray analysis of A375(DRO) after TZD and combination rexinoid/TZD treatment in which the calcium binding protein S100A2 had increased expression after rexinoid or TZD treatment and a synergistic increase to combination treatment. Increased S100A2 expression is dependent on an intact PPARγreceptor, but it is not sufficient to mediate the antiproliferative effects of rexinoid/TZD treatment. Over expression of S100A2 enhanced the effect of rexinoid and TZD treatment while inhibition of S100A2 expression attenuated the response to rexinoid/TZD treatment, suggesting that S100A2 is necessary for optimal response to RXR and PPARγactivation by respective ligands. In summary, we have identified potential downstream mediators of rexinoid and TZD treatment in a poorly differentiated melanoma and found that alterations in S100A2 expression affect RXR and PPARγsignaling in A375(DRO) cells. These studies provide insight into potential mechanisms of tumor response or resistance to these novel therapies.


  • Open Access

    Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

    by Joshua P Klopper, Vibha Sharma, Andrew Berenz, William R Hays, Michele Loi, Umarani Pugazhenthi, Sherif Said, Bryan R Haugen

    Metastatic melanoma has a high mortality rate and suboptimal therapeutic options. Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid × receptor selective agonist, and thiazolidinediones (TZD), PPARγ selective ligands, as novel treatments.